Lv 2016.

Methods	Study design: Randomised clinical trial Study duration: January 2013 to January 2014 Duration of follow‐up: 2 years Setting: Hospital
Participants	Age (mean ± SD, range): TACE + RFA: 52.25 ± 2.12 years, 34‐76 years; TACE alone: 52.61 ± 2.13 years, 34‐77 years Male (n/total): TACE + RFA: 27/30; TACE: 25/30
Interventions	TACE + RFA group (n = 30): TACE: Chemotherapeutic drugs: 5‐fluorouracil 0.5‐1 g, hydroxy camptothecin 10 g, and epirubicin 10‐40 mg. Total sessions of TACE ranged between 1‐3, with an interval of 4‐5 weeks. RFA: The interval between TACE and RFA was 3‐4 weeks. CT‐guided RFA TACE group (n = 30): Chemotherapeutic drugs: 5‐fluorouracil 0.5‐1 g, hydroxy camptothecin 10 g, and epirubicin 10‐40 mg. Total sessions of TACE ranged between 1‐3, with an interval of 4‐5 weeks.
Outcomes	Serum level of AFP Tumour response, classified as complete response, partial response, stable, and progression 2‐year survival rate Adverse events
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.